Contract research organization
Outsourcing in Clinical Research
Over the last few years, the pharmaceutical industry has seen large companies use ‘downsizing’ strategies more and concentrating resources on core skills. As industry margins come under increasing pressure, companies could begin outsourcing aspects of their development, manufacturing or marketing processes so as to concentrate on their core specialties. Outsourcing has been particularly influential in the pharmaceutical industry as the success of a large pharmaceutical company depends on competence in fields as diverse as combinatorial chemistry, computer integrated manufacturing and marketing medicines directly to consumers. External cost pressures have acted as a major driver for the pharmaceutical outsourcing market. At bottom, the outsourcing market has developed in response to the downward and upward cost pressures exerted on pharmaceutical manufacturers’ profit margins. Given that such pressures are likely to increase in the future, CROs will become more and more important strategic partners for pharmaceutical companies. It is, therefore, in the latter’s interest to consider probable developments in the CRO market and its major players.
Reasons for outsourcing to contract research organizations
Outsourcing offers a number of advantages to the companies. These include: Reduces the time (8 to 15 years) required to develop and bring a new drug to market Sponsor can convert the fixed costs of maintaining the personnel, expertise and facilities like data management necessary for clinical trial management into variable costs Non-availability of services in-house Knowledge of regulatory affairs in a particular country of interest Increased complexity of clinical trials Increased amount of data required from clinical trials Multinational and multi-center nature of current clinical trials Large requirement of patient populations Regionalized diseases
CRO market size and growth
Global industry analysers estimated that pharmaceutical and biotechnology companies spent approximately $57 billion on R & D in 2005, out of which an estimated $14 billion was used for the outsourcing services offered by the CRO industry.This figure is expected to increase further with the broadening of the spectrum of services outsourced to cover
the entire value chain. As the outsourced services to China and India move up the value chain to cover phase 1/2 trials, the total contracts value may go up to $20 billion by 2010.
Differences between a CRO and eCRO
A Contract Research Organization (CRO) is a type of organization that offers a wide range of pharmaceutical drug biologic and device development services. These services can include: product and process development, toxicology, clinical trial management from Phase 1 to Phase 4 (including study startup, monitoring and closeout), data management, and biostatistics, medical writing and regulatory affairs (including consultations and regulator submissions). An eCRO provides all of the above services, but has developed their own electronic tools to support the drug, biologic and device development processes. These tools include: web-based document management (including access and version control, as well as electronic signatures), clinical trial management system (CTMS), autoencoding of adverse events (MedDRA concomitant medications (WHO DRUG), and electronic data capture (EDC) which eliminates doublekey data entry. Other tools can include mapping to CDISC Clinical_Data_Interchange_Standards_Consortium, electronic newsletters, eCTD preparation for IND and NDA, etc.